Loading company details...
Beta
Latest Form 4 (Mar 6, 2024): Israel Biotech Fund I, L.P. (Director): Exercise/Conversion of 3,750,000 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 6, 2024 | Israel Biotech Fund I, L.P. | Exercise/Conversion | 3,750,000 | n/a |
| Feb 12, 2024 | Israel Biotech Fund I, L.P. | Exercise/Conversion | 1,926,221 | $770.5K |
| Nov 21, 2023 | Israel Biotech Fund I, L.P. | Purchase | 2,812,500 | n/a |
| Oct 31, 2023 | Israel Biotech Fund I, L.P. | Purchase | 658,858 | n/a |
| Jan 23, 2023 | David Sidransky | Grant/Award | 46 | n/a |
| Jan 23, 2023 | Murray A. Goldberg | Grant/Award | 3,279 | n/a |
| Jan 23, 2023 | Vered Bisker-Leib | Grant/Award | 1,639 | n/a |
| Jan 23, 2023 | Robert J. Spiegel | Grant/Award | 3,279 | n/a |
| May 5, 2020 | Molly Henderson, Executive Vice President & CFO | Grant/Award | 50,000 | n/a |
| May 5, 2020 | Samir N. Khleif | Grant/Award | 13,000 | n/a |